» Articles » PMID: 24324968

Novel Natural Structure Corrector of ApoE4 for Checking Alzheimer's Disease: Benefits from High Throughput Screening and Molecular Dynamics Simulations

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2013 Dec 11
PMID 24324968
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A major genetic suspect for Alzheimer's disease is the pathological conformation assumed by apolipoprotein E4 (ApoE4) through intramolecular interaction. In the present study, a large library of natural compounds was screened against ApoE4 to identify novel therapeutic molecules that can prevent ApoE4 from being converted to its pathological conformation. We report two such natural compounds PHC and IAH that bound to the active site of ApoE4 during the docking process. The binding analysis suggested that they have a strong mechanistic ability to correct the pathological structural orientation of ApoE4 by preventing repulsion between Arg 61 and Arg 112, thus inhibiting the formation of a salt bridge between Arg 61 and Glu 255. However, when the molecular dynamics simulations were carried out, structural changes in the PHC-bound complex forced PHC to move out of the cavity thus destabilizing the complex. However, IAH was structurally stable inside the binding pocket throughout the simulations trajectory. Our simulations results indicate that the initial receptor-ligand interaction observed after docking could be limited due to the receptor rigid docking algorithm and that the conformations and interactions observed after simulation runs are more energetically favored and should be better representations of derivative poses in the receptor.

Citing Articles

Perspectives on the Role of as a Therapeutic Target for Alzheimer's Disease.

Patel K, Srivastava S, Kushwah S, Mani A J Alzheimers Dis Rep. 2022; 5(1):899-910.

PMID: 35088039 PMC: 8764632. DOI: 10.3233/ADR-210027.


Identification of GCC-box and TCC-box motifs in the promoters of differentially expressed genes in rice (Oryza sativa L.): Experimental and computational approaches.

Prajapati G, Pandey B, Mishra A, Baek K, Pandey D PLoS One. 2019; 14(4):e0214964.

PMID: 31026257 PMC: 6485614. DOI: 10.1371/journal.pone.0214964.


ApoE: In Vitro Studies of a Small Molecule Effector.

Mondal T, Wang H, DeKoster G, Baban B, Gross M, Frieden C Biochemistry. 2016; 55(18):2613-21.

PMID: 27065061 PMC: 4976638. DOI: 10.1021/acs.biochem.6b00324.


Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.

Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A BMC Bioinformatics. 2015; 16 Suppl 19:S10.

PMID: 26695135 PMC: 4686784. DOI: 10.1186/1471-2105-16-S19-S10.


Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.

Goyal S, Jamal S, Shanker A, Grover A BMC Genomics. 2015; 16 Suppl 5:S8.

PMID: 26041145 PMC: 4460657. DOI: 10.1186/1471-2164-16-S5-S8.


References
1.
Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

2.
. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012; 8(2):131-68. DOI: 10.1016/j.jalz.2012.02.001. View

3.
Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

4.
Ostrov D, Hernandez Prada J, Corsino P, Finton K, Le N, Rowe T . Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Antimicrob Agents Chemother. 2007; 51(10):3688-98. PMC: 2043263. DOI: 10.1128/AAC.00392-07. View

5.
Pericak-Vance M, Yamaoka L, Haynes C, Speer M, Haines J, Gaskell P . Genetic linkage studies in Alzheimer's disease families. Exp Neurol. 1988; 102(3):271-9. DOI: 10.1016/0014-4886(88)90220-8. View